IL-23 p19 Antibody Therapy for Psoriasis After TNF Nonresponse
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psoriasis, such as TNF inhibitors, are not effective for all patients, and neutralizing both IL-12 and IL-23 can impact important host defense mechanisms, necessitating a targeted approach to inhibit IL-23 specifically.
Innovation Solution
Administering guselkumab, a fully human IgG1 lambda monoclonal antibody that binds to the p19 subunit of IL-23, in a safe and effective amount, to treat psoriasis in patients non-responsive to TNF inhibitors, with a dosing regimen of initial and subsequent doses every 8 weeks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-IL-12p40 antibodies are used to treat psoriasis, then disease suppression is achieved, but both IL-12 and IL-23 are neutralized impacting host defense mechanisms
Solution Approach 1:
The invention segments the target neutralization by developing guselkumab, an antibody that specifically binds to the p19 subunit of IL-23, thereby selectively neutralizing IL-23 while leaving IL-12 intact. This segmentation allows differential treatment of the two cytokines that share the p40 subunit, achieving disease suppression without compromising IL-12-mediated host defense mechanisms
Solution Approach 2:
The invention extracts the specific p19 subunit of IL-23 as the unique target for neutralization. By designing guselkumab to bind specifically to p19 rather than the shared p40 subunit, the therapy extracts and targets only the pathogenic IL-23 component while preserving the functional IL-12 pathway, thus resolving the contradiction between efficacy and safety
2Adaptability or versatility
If TNF inhibitors are used as first-line treatment, then initial therapy is provided, but they are not effective for all patients including non-responders
Solution Approach 1:
The invention implements a dynamic treatment approach where guselkumab is positioned as a subsequent therapy option for patients who do not respond to TNF inhibitors. This dynamic strategy allows treatment to be adapted based on patient response, ensuring that non-responders receive an alternative mechanism of action targeting the IL-23 pathway rather than the TNF pathway
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves significant clinical and molecular response in psoriasis patients, reaching endpoints of IGA score of cleared or minimal disease and 90-100% improvement in PASI response.
Implementation Method 1
guselkumab, a fully human IgG1 lambda monoclonal antibody that binds to the p19 subunit of IL-23
Data Source
AI summary
A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.